INTROduCTION Acute cardiogenic pulmonary edema (ACPE) can be caused by a variety of insults including, among others, dietary indiscretion, medication non-compliance, hypertensive crisis, arrhythmias, acute coronary syndromes and valvular lesions. A variety of modalities exist to treat ACPE such as standard medical care including venodilators, after load reduction, inotropic medications and diuretics; insult specific modes like rate controlling agents in tachyarrhythmia; noninvasive positive pressure ventilation modes (NPPV) including continuous positive airway pressure (CPAP) and bi-level positive airway pressure (BiPAP); and finally, invasive ventilation/intubation. Several recent meta-analyses (MAs) concluded that NPPV provided a significant mortality benefit in patients with ACPE.
KEy wORds
bi-level positive airway pressure, continuous positive airway pressure, positive pressure ventilation, pulmonary edema based on lack of awareness of their existence but rather on concern regarding their quality, methodology and appropriateness for inclusion.
To avoid the possibility that the choice of studies included in this modified analysis might influence its result, three sets of RCTs were used and combined with the 3CPO data. TAbLE 1 shows those RCTs included in 3 separate analyses: the first duplicated the Cochrane analysis (Cochrane Set); the second included all trials identified within any of the MAs (Comprehensive Set); and the third included only those trials agreed to among four out of the five of the MAs (Quality Set).
All statistical analyses were performed with Review Manager (Revman Version 5) utilizing both fixed and variable effect models. 7 In hospital, mortality was the end point of all previous MAs, but the 3CPO trial reported only 7 and 30 day mortality. Therefore, the combined MA/3CPO data was analyzed with both 7 and 30 day mortality data. Delclaux 2000 , Ferrer 2004 , Lin 1991 , Sharon 2000 and Thys 2002 in their analyses. Reviewing individual MAs revealed that the exclusion of these trials was not Abbreviations: see TAbLE 1 of the benefit of NPPV that had accumulated at the time of the trial. With this evidence, there was no ethical opportunity to design the trial in the rigorous non-crossover fashion that would accurately estimate the mortality benefit of NPPV. This limitation and restriction in trial design did not exist in the earlier RCTs completed before the evidence for the benefit of NPPV was so compelling. High rates of crossover/rescue NPPV were explicit exclusion criteria in some MAs. Owing to its design and crossover, the 3CPO trial would not have been included in Masip's MA. TAbLE 1 shows that very few of the RCTs included within the MAs allowed crossover within the trial methodology.
The influence of NPPV/rescue NPPV/crossover on avoiding intubation and the mortality benefit of avoiding any intubation are overlapping variables that merit individual consideration in assessing the benefit of NPPV. The risks of intubation include ventilator associated pneumonia, tracheal injury and prolonged intensive care unit and hospital stay. 4 Peter et al. estimated that in ACPE it is only necessary to treat 6 or 7 with NPPV to avoid one intubation.
2 Peter's MA found intubation rates in the SMC and NPPV groups of 27% and 12%, respectively. 2 In dramatic contrast to all of the MAs identified in this paper, the 3CPO trial had very low intubation rates that were the same (3%) in both the SMC and NPPV groups. Did the crossover allowed within the 3CPO trial reduce intubations in the SMC group and did this in turn affect the predicted mortality benefit of NPPV?
Significant differences found between the 3CPO trial and previous MAs include: the high degree of crossover/rescue NPPV found in the 3CPO trial; the overall low rate of intubation in the 3CPO trial; and the equivalent rate of intubation between the SMC and NPPV groups in the 3CPO trial. These differences help explain the important REsuLTs The FIGuRE shows that when the 3CPO data (30 day mortality) is added to the Cochrane MA, there continues to be a significant mortality benefit of NPPV in ACPE (fixed effect model, risk ratio 0.75, CI 0.61-0.92). TAbLE 2 gives the results of all the analyses identified in TAbLE 1. A sensitivity analysis, taking into account all modes of analysis and combinations of RCTs, continues to predict a statistically significant mortality benefit of NPPV in ACPE. Significant heterogeneity was not observed in any of the analyses performed (all I 2 below 10%).
dIsCussION While the modified analysis predicts a continued mortality benefit, it remains of inter est to examine reasons for the RCT-MA incongruence. The post 3CPO trial discussion identifies many reasons for the incongruence.
8 Among these reasons, two overlapping and key factors are crossover and intubation rates. Only a rigid trial not allowing crossover from the standard medical care (SMC) group into the NPPV group can accurately estimate mortality benefit. This was not the case in the 3CPO trial which allowed, after only 2 hours of separate randomization, full clinical discretion in patient management. Furthermore, within 2 hours of randomization, 19% of SMC patients (those with worsening respiratory para meters) had their therapy escalated to NPPV and intubation (only 1% were intubated, the other 18% were rescued with NPPV). The paper does not reveal how many patients crossed into the NPPV group after the 2 hour trial period. Considering the degree of crossover and rescue NPPV within the 3CPO trial, rather than address the mortality benefit of NPPV in ACPE, the trial simply evaluates whether in patients who clinically merit NPPV, a short delay in initiating NPPV increases mortality.
The high crossover/early rescue NPPV within the 3CPO trial likely reflects evidence RCT-MA incongruence addressed in this paper. Prior to the 2008 3CPO trial there was a state of agreement within the literature, and at least five separate MAs concluded, that NPPV in ACPE provided a strong, significant mortality benefit. Although the 3CPO trial did not confirm this mortality benefit, when its data is analyzed together with a comprehensive set of RCTs (at the end of 2005), in varying combinations and analysis modes (fixed and variable), in every instance there continues to be a statistically significant mortality benefit of NPPV in ACPE. The high rate of crossover and low intubation rates within the 3CPO trial were in part responsible for its lack of mortality benefit. Therefore, the combined mortality estimate of this modified MA is an underestimation of the true mortality benefit. The results of this modified MA together with a review of the methodology of the 3CPO trial support an important and significant mortality benefit of NPPV in ACPE.
